2. Pay no attention to the CSRs behind the curtain

In a move lauded by clinical trial transparency activists, the EMA has begun to release  the full clinical study reports (CSRs) submitted for drug approval on their website. These aren’t the paired-down, not-quite-as-public-relations-focused-as-a-press-release-but-still-not-the-whole-picture versions submitted in scientific journals, and they include all the info a sponsor might not want to publish themselves—like the details of a drug’s adverse effects. The reports will be redacted for patient data and commercially confidential information, and the EMA will be retroactively posting CSRs for products (approved, or otherwise) submitted to the agency for review since Jan. 1, 2015. In the meantime, maybe try some light reading with the 260,000 pages released so far.